Key result
PRKAR1A mutations in Cushing syndrome linked to lower BMI and increased periadrenal cAMP and PKA.
Why the study?
Does PRKAR1A mutation status affect adiposity and PKA signaling in patients with Cushing syndrome?
Observational (n=51)
No
Does PRKAR1A mutation status affect adiposity and PKA signaling in patients with Cushing syndrome?
Germline defects of PKA (PRKAR1A mutations) in Cushing syndrome are associated with increased PKA signaling in periadrenal adipose tissue and a less obese phenotype.
Answers are grounded in this paper and cite their sources.
May warrant adiposity monitoring in PRKAR1A-related CS; leaves open whether PKA dysregulation drives obesity beyond cortisol excess.
CONTEXT: The cAMP signaling pathway is implicated in bilateral adrenocortical hyperplasias. Bilateral adrenocortical hyperplasia is often associated with ACTH-independent Cushing syndrome (CS) and may be caused by mutations in genes such as PRKAR1A, which is responsible for primary pigmented nodular adrenocortical disease (PPNAD). PRKAR1A regulates cAMP-dependent protein kinase (PKA), an essential enzyme in the regulation of adiposity. Although CS is invariably associated with obesity, its different forms, including those associated with PKA defects, have not been compared. OBJECTIVE: The purpose of this study was to characterize the phenotypic and molecular differences in periadrenal adipose tissue (PAT) between patients with CS with and without PRKAR1A mutations. DESIGN AND SETTING: Samples from adrenalectomies of 51 patients were studied: patients with CS with (n = 13) and without (n = 32) PRKAR1A mutations and a comparison group with aldosterone-producing adenomas (APAs) (n = 6). In addition, clinical data from a larger group of patients with Cushing disease (n = 89) and hyperaldosteronism (n = 26) were used for comparison. METHODS: Body mass index (BMI), abdominal computed tomography scans, and cortisol data were collected preoperatively. PAT was assayed for PKA activity, cAMP levels, and PKA subunit expression. RESULTS: BMI was lower in adult patients with CS with PRKAR1A mutations. cAMP and active PKA levels in PAT were elevated in patients with CS with PRKAR1A mutations. CONCLUSIONS: Increased PKA signaling in PAT was associated with lower BMI in CS. Differences in fat distribution may contribute to phenotypic differences between patients with CS with and without PRKAR1A mutations. The observed differences are in agreement with the known roles of cAMP signaling in regulating adiposity, but this is the first time that germline defects of PKA are linked to variable obesity phenotypes in humans.
No takes yet. Share an insight, caveat, or question.
London et al. (2013) conducted an observational in Cushing syndrome (n=51). PRKAR1A mutations vs. Cushing syndrome without PRKAR1A mutations was evaluated on Body mass index (BMI) (p=<0.05). PRKAR1A mutations in patients with Cushing syndrome were associated with significantly lower body mass index and increased cAMP and active PKA levels in periadrenal adipose tissue.
Synapse has enriched 10 related papers. Consider them for comparative context: